Skip to main content

Table 5 Common, all-causality adverse events reported in patients with OS ≥24 versus < 24 months in the axitinib titration arm

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Adverse event,a n (%)

OS ≥24 months n = 33

OS < 24 months n = 20b

All Grades

Grade ≥ 3

All Grades

Grade ≥ 3

Any

33 (100)

24 (73)

19 (95)

11 (55)

Diarrhoea

27 (82)

7 (21)

7 (35)

0

Hypertension

24 (73)

7 (21)

10 (50)

3 (15)

Fatigue

18 (55)

1 (3)

9 (45)

2 (10)

Nausea

14 (42)

1 (3)

10 (50)

2 (10)

Hand–foot syndrome

14 (42)

1 (3)

4 (20)

1 (5)

Hypothyroidism

14 (42)

0

4 (20)

0

Decreased appetite

12 (36)

2 (6)

8 (40)

2 (10)

Weight decrease

12 (36)

6 (18)

4 (20)

0

Vomiting

11 (33)

3 (9)

8 (40)

1 (5)

Dysphonia

11 (33)

0

7 (35)

1 (5)

Arthralgia

10 (30)

0

3 (15)

1 (5)

Stomatitis

10 (30)

1 (3)

0

0

Mucosal inflammation

9 (27)

1 (3)

3 (15)

1 (5)

Proteinuria

9 (27)

2 (6)

3 (15)

0

  1. Abbreviation: OS overall survival
  2. aReported by ≥25% in either group
  3. bExcluded 3 patients who were censored < 24 months in OS